AnaptysBio Q3 2024 Earnings Report

AnaptysBio EPS Results

• Actual EPS: -$1.14
• Consensus EPS: -$1.72
• Beat/Miss: Beat by +$0.58
• One Year Ago EPS: N/A

AnaptysBio Revenue Results

• Actual Revenue: $30.02 million
• Expected Revenue: $7.92 million
• Beat/Miss: Beat by +$22.10 million
• YoY Revenue Growth: N/A

AnaptysBio Announcement Details

• Quarter: Q3 2024
• Date: 11/5/2024
• Time: After Market Closes
• Conference Call Date: Tuesday, November 5, 2024
• Conference Call Time: 3:00PM ET

AnaptysBio (NASDAQ:ANAB) is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company's technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders. Among its leading candidates is ANB020, an anti-IL-33 antibody being evaluated for atopic dermatitis and eosinophilic asthma, and ANB019, an anti-IL-36 receptor antibody in development for generalized pustular psoriasis. In addition to its clinical assets, AnaptysBio is advancing several preclinical programs aimed at novel immuno-oncology targets, reflecting its commitment to broadening the therapeutic potential of its platform.

AnaptysBio has established strategic partnerships to enhance its research and development efforts. These collaborations include agreements with major pharmaceutical companies to co-develop and commercialize select antibody candidates. Through these alliances, AnaptysBio gains access to expanded development expertise, global regulatory capabilities, and commercialization support, while retaining rights to key programs emerging from its discovery engine.

Since completing its initial public offering in 2016, AnaptysBio has grown its team and infrastructure to support both early-stage discovery and late-stage clinical development. The company is led by President and Chief Executive Officer Hamza Suria and maintains research operations in the United States. AnaptysBio’s mission is to deliver differentiated antibody therapeutics that address unmet medical needs in inflammatory diseases and cancer.